Background And Aims: Sildenafil blocks phosphodiesterase type 5 which degrades nitric oxide (NO) stimulated 3'5'-cyclic monophosphate (cGMP), thereby relaxing smooth muscle cells in various organs. We used sildenafil as a tool to investigate the role of the NO-cGMP pathway in the oesophagus of healthy volunteers and patients with hypercontractile oesophageal motility disorders.

Methods: Six healthy male volunteers participated in a randomised double blind study on two separate days before and one hour after oral intake of either sildenafil 50 mg or placebo. Oesophageal manometry was performed to determine vector volume of the lower oesophageal sphincter (LOS) and pressure amplitudes of the oesophageal body. Four of the volunteers underwent 12 hour ambulatory oesophageal manometry on two separate days, once with sildenafil 50 mg and once with placebo. An activity index for spontaneous swallowing was calculated for every hour of the study. Eleven patients with hypercontractile oesophageal motility disorders took part in an open study of the effect of 50 mg sildenafil on manometric features of their disorder and on the clinical response to sildenafil taken as required.

Results: In healthy subjects, sildenafil significantly reduced LOS pressure vector volume and pressure amplitudes in the distal half of the oesophageal body. In three of four subjects the inhibitory effect of sildenafil lasted at least eight hours. In nine of 11 patients, manometric improvement after sildenafil was observed but only four had an improvement in oesophageal symptoms with sildenafil taken as required. Two of these four patients however experienced side effects and did not want to continue treatment.

Conclusions: Sildenafil lowers LOS pressure and propulsive forces in the body of the oesophagus of healthy subjects as well as in patients with nutcracker oesophagus, hypertensive LOS, and achalasia. The effect of sildenafil on the oesophageal body may last for up to eight hours in healthy volunteers. A subset of patients with hypertensive LOS or nutcracker oesophagus may benefit from sildenafil but side effects are a limiting factor.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773249PMC
http://dx.doi.org/10.1136/gut.50.6.758DOI Listing

Publication Analysis

Top Keywords

sildenafil
14
healthy subjects
12
los pressure
12
oesophageal body
12
oesophageal
10
sildenafil oesophageal
8
oesophageal motor
8
oesophagus healthy
8
healthy volunteers
8
patients hypercontractile
8

Similar Publications

Effect of long and short half-life PDE5 inhibitors on HbA1c levels: a systematic review and meta-analysis.

EClinicalMedicine

February 2025

Human Stem Cell and Genome Engineering Center, University of California Los Angeles David Geffen School of Medicine, UCLA - CHS 36 - 125/133/143 650 Charles E. Young Dr. South, Los Angeles, CA, 90095, USA.

Background: Phosphodiesterase 5 (PDE5) inhibitors, owing to their mechanism of action, have been gaining recognition as a potential case of drug repurposing and combination therapy for diabetes treatment. We aimed to examine the effect of long and short half-life PDE5 inhibitors have on Haemoglobin A1c (HbA1c) levels.

Methods: A systematic review and meta-analysis was conducted of randomised controlled trials (RCTs) in people with elevated HbA1c (>6%) to assess mean difference in HbA1c levels from baseline versus controls after any PDE5 inhibitor intervention of ≥4 weeks, excluding multiple interventions.

View Article and Find Full Text PDF

Acquired Dyschromatopsia and Its Link to Drug Toxicity.

Cureus

December 2024

Optometric - Glaucoma, Leicester Royal Infirmary, Leicester, GBR.

Colour vision defects (CVDs) can be both congenital and acquired, with acquired dyschromatopsia often associated with medication toxicity. This review explores various standardised colour vision tests used to detect these defects, including the Ishihara plate test, Farnsworth-Munsell 100 hue test, and anomaloscopes. These methods are evaluated for their effectiveness in diagnosing CVDs, particularly in acquired conditions.

View Article and Find Full Text PDF

Prolonged pleural drainage and chylothorax are common in postoperative Fontan patients and are associated with increased morbidity and mortality. Multiple medical and interventional treatment strategies exist and vary between centers. This is a retrospective multicenter observational cohort study of pediatric patients who underwent Fontan operation at 8 pediatric cardiac surgical institutions from 1/1/2019 to 12/31/2021.

View Article and Find Full Text PDF

Rationale: Chylothorax is a rare adverse effect that is associated with dasatinib, a tyrosine kinase inhibitor administered for chronic myeloid leukemia (CML) treatment. Most reported cases have described standard dosing. In this case report, we described a 43-year-old male patient with CML who developed chylothorax after 4 years of low-dose dasatinib therapy.

View Article and Find Full Text PDF

Predicting right ventricular failure after left ventricular assist device implant: A novel approach.

ESC Heart Fail

January 2025

Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Aims: Right ventricular (RV) failure (RVF) after left ventricular assist device (LVAD) implant is an important cause of morbidity and mortality. Modern, data-driven approaches for defining and predicting RVF have been under-utilized.

Methods: Two hundred thirty-two patients were identified with a mean age of 55 years; 40 (17%) were women, 132 were (59%) Caucasian and 74 (32%) were Black.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!